Equity Details
Price & Market Data
Price: $16.85
Daily Change: -$0.40 / 2.37%
Daily Range: $16.45 - $16.85
Market Cap: $15,889,719,296
Daily Volume: 2,154
Performance Metrics
1 Week: -4.17%
1 Month: -8.73%
3 Months: 36.42%
6 Months: 19.17%
1 Year: 55.41%
YTD: 5.63%
About Akeso, Inc. (AKESF)
Detailed market insights for Akeso, Inc. (AKESF). Current price: 16.85, daily change: -$0.40 / 2.37%. Market cap: 15,889,719,296. YTD, 1-week, 1-month performance are highlighted.
Company Details
Employees: 3761
Sector: Health technology
Industry: Pharmaceuticals: major
Country: China
Details
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. Akeso, Inc. has collaboration with Inovio Pharmaceuticals, Inc. to evaluate INOVIO's INO-5412 in combination with cadonilimab as a potential treatment for glioblastoma (GBM). The company was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.